You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

25 Results
Guidelines and Advice
Jan 2014
Guidelines and Advice
Jan 2014
Guidelines and Advice
Jan 2014
Drug
Other Name(s): Temodal®
Aug 2025
Drug
Other Name(s): Trelstar® (Allergan Pharma)
Oct 2014
Drug
Other Name(s): Mekinist®
Jun 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Aug 2025
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Jun 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant
Funding:
ODB - General Benefit
    temozolomide
Aug 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
Sep 2025
Drug
Other Name(s): Tukysa™
Feb 2025

Pages